Title |
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
|
---|---|
Published in |
Frontiers in Pharmacology, January 2013
|
DOI | 10.3389/fphar.2013.00039 |
Pubmed ID | |
Authors |
Rickard E. Malmström, Brian B. Godman, Eduard Diogene, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Brzezinska, Anna Bucsics, Stephen Campbell, Alessandra Ferrario, Alexander E. Finlayson, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Iñaki Gutiérrez-Ibarluzea, Alan Haycox, Krystyna Hviding, Harald Herholz, Mikael Hoffmann, Saira Jan, Jan Jones, Roberta Joppi, Marija Kalaba, Christina Kvalheim, Ott Laius, Irene Langner, Julie Lonsdale, Sven-Äke Lööv, Kamila Malinowska, Laura McCullagh, Ken Paterson, Vanda Markovic-Pekovic, Andrew Martin, Jutta Piessnegger, Gisbert Selke, Catherine Sermet, Steven Simoens, Cankat Tulunay, Dominik Tomek, Luka Vončina, Vera Vlahovic-Palcevski, Janet Wale, Michael Wilcock, Magdalena Wladysiuk, Menno van Woerkom, Corrine Zara, Lars L. Gustafsson |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | <1% |
Austria | 1 | <1% |
Brazil | 1 | <1% |
Slovenia | 1 | <1% |
Luxembourg | 1 | <1% |
Unknown | 109 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 25 | 22% |
Student > Ph. D. Student | 12 | 11% |
Researcher | 7 | 6% |
Professor | 7 | 6% |
Student > Bachelor | 7 | 6% |
Other | 29 | 25% |
Unknown | 27 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 39% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
Social Sciences | 9 | 8% |
Economics, Econometrics and Finance | 6 | 5% |
Agricultural and Biological Sciences | 4 | 4% |
Other | 11 | 10% |
Unknown | 30 | 26% |